TriCelX Files IND with FDA & Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis
UC-Mesenchymal Signaling Cells (MSCs)
IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis
THE STAR, FRISCO, TX, UNITED STATES, March 30, 2026 /EINPresswire.com/ -- RMAT DESIGNATION REQUEST
XytriX™ has been submitted for FDA Regenerative Medicine Advanced Therapy (RMAT) designation concurrent with this IND — a pathway reserved for therapies with preliminary evidence of potential to address serious or life-threatening conditions, unlocking priority review, rolling BLA submission, and early, frequent FDA engagement.
FRISCO, Texas, March 30, 2026 — TriCelX, Inc. ("TriCelX"), a global translational leader in evidence-based biologics, today announced the submission of a Phase 1/2 Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for XytriX™, its proprietary allogeneic umbilical cord tissue-derived mesenchymal stem cell (hUC-MSC) biotherapeutic for the treatment of adult patients with Grade I–IV Knee Osteoarthritis (KOA). Concurrent with the IND filing, TriCelX has submitted a formal request for Regenerative Medicine Advanced Therapy (RMAT) designation — one of the FDA's highest-priority development pathways — underscoring the company's confidence in XytriX™ as a potentially transformative, disease-modifying treatment for a condition affecting hundreds of millions worldwide.
A Disease in Desperate Need of a Better Answer
Osteoarthritis (OA) is the world's most prevalent joint disease, affecting more than 500 million people globally and one in seven American adults. The knee is the most commonly affected joint. OA imposes a staggering economic burden exceeding $137 billion in the United States alone and is a leading cause of disability, chronic pain, and diminished quality of life. Today's standard-of-care interventions — including corticosteroid injections — manage symptoms at best, and carry serious risks including cartilage degradation, tendon rupture, hyperglycemia, and rapid joint destruction. No disease-modifying therapy is currently approved.
XytriX™: A Potential Disease-Modifying Biotherapeutic
XytriX™ is a next-generation, off-the-shelf allogeneic cell therapy derived from Wharton's jelly of donated human umbilical cords. Unlike existing symptomatic treatments, XytriX™ is designed to address the underlying biology of knee OA through multiple complementary mechanisms — including immunomodulation, anti-inflammatory signaling, stimulation of endogenous progenitor cells, promotion of cartilage formation and collagen deposition, and cytoprotection against cell death. More than two decades of published evidence on hUC-MSCs support a favorable safety profile, with a landmark 2026 systematic review and meta-analysis reporting no serious adverse events attributable to MSC therapy across randomized controlled trials and a favorable short-to-medium-term safety profile.
XytriX™ is manufactured to exacting standards at TriCelX's FDA-registered cGMP/cGTP-compliant facility in Frisco, Texas. Each batch is rigorously tested for sterility, endotoxin levels, and MSC identity marker profiles, and is cryopreserved in a serum-free, animal component-free medium — ensuring consistency, purity, and readiness for clinical use.
Why RMAT Designation Matters
RMAT designation is granted by the FDA to regenerative medicine therapies that show preliminary clinical evidence supporting the potential to address serious or life-threatening conditions. If granted, RMAT designation would provide TriCelX with a suite of accelerated development advantages:
▸ Accelerated FDA Engagement: Early and frequent interactions with the FDA's Center for Biologics Evaluation and Research (CBER)/Office of Tissues and Advanced Therapies (OTAT)
▸ Rolling BLA Review: The ability to submit and receive review of sections of the Biologics License Application (BLA) on a rolling basis, compressing the path to approval.
▸ Priority Review: An expedited BLA review timeline, consistent with the FDA's Priority Review designation framework.
▸ Additional Development Tools: Use of accelerated approval and breakthrough therapy designation tools to further streamline development.
TriCelX's concurrent RMAT request is grounded in the extensive published body of clinical evidence demonstrating MSC efficacy and safety in knee OA, including multiple randomized controlled trials, systematic reviews, and meta-analyses — culminating in the 2026 Wang et al. systematic review confirming favorable outcomes with intra-articular MSC therapy.
Phase 1/2 Clinical Trial Design
The Phase 1/2 trial — formally titled "A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Intra-Articular (IA) Injection of XytriX™ in Adult Subjects with Grade I–IV Knee Osteoarthritis (KOA)" — is a prospective, single-center study enrolling approximately 50 adult subjects at TriCelX's Frisco, Texas clinical site. Enrolled subjects will receive a single intra-articular injection of 30 million hUC-MSCs (~3 mL) — a dose selected based on published evidence demonstrating optimal efficacy with an acceptable safety margin.
Participants will be monitored over a 180-day follow-up period with assessments at 1, 3, and 6 months using validated, clinically rigorous outcome measures including the Knee Injury and Osteoarthritis Outcome Score (KOOS), WOMAC Index, 100-mm Visual Analog Scale (VAS) for pain, SF-36 Quality of Life survey, and the Timed Up and Go (TUG) functional test. A Data Safety Monitoring Board (DSMB) will provide independent safety oversight throughout the trial.
“The submission of our IND and our concurrent request for RMAT designation represent defining milestones for TriCelX and, more importantly, for the hundreds of millions of patients worldwide who are suffering from osteoarthritis and have run out of options. XytriX™ is not simply another symptomatic treatment — it is designed to harness the body's own regenerative biology to address the root cause of joint destruction. We are proud of the scientific rigor embedded in every aspect of this submission and look forward to a productive collaboration with the FDA as we advance this promising therapy toward patients.”
— Jakes Jordaan, Founder and Chief Executive Officer, TriCelX, Inc.
About TriCelX, Inc.
Led by world-class scientists and surgeons, TriCelX is a global translational biologics company dedicated to advancing evidence-based, personalized regenerative medicine therapies. With operations in Texas, Utah, and Antigua, TriCelX offers globally harmonized cell therapy solutions designed to harness the regenerative power of afterbirth-derived Mesenchymal Signaling Cells (MSCs). TriCelX's proprietary platform enables MSCs to differentiate into connective tissue, regenerate neurons, reduce neuroinflammation, and modulate the immune system. In addition to its XytriX™ program, TriCelX is developing novel biological medical countermeasures to address the unique battlefield challenges faced by the U.S. military. For more information, visit www.tricelx.com
Forward-Looking Statements
Certain statements in this press release are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. Such factors include, but are not limited to, the uncertainties inherent in the drug development process, including regulatory approvals and clinical trial outcomes. TriCelX undertakes no obligation to update forward-looking statements to reflect changed circumstances.
Media Contact
Kathryn Dziedzic | TriCelX, Inc.
📞 (855) 874-2359 ✉ media@tricelx.com 🌐 www.tricelx.com
Kathryn Dziedzic
TriCelX
+1 855-874-2359
email us here
Visit us on social media:
Instagram
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
